Nemara announced the sponsorship of Celie Gross for their latest launch Wearable Injectors of On Drug Delivery. The product is designed to suffice the unmet drug delivery needs in chronic diseases. The lack of simultaneous response to the challenges related to biologics, self-administration, connectivity, and sustainability in one device is a driving force behind the thought that it would be good for patients who suffer from chronic disease to have an intelligent, sustainable on-body injector.
Merck KGaA announces a collaboration with InnoCore Pharmaceuticals to provide Innocare with the proprietary SynBiosys biodegradable polymer platform. It is a drug delivery platform developed to reduce the hurdles in injectable formulation. This collaboration will enable new and potentially life-changing drugs to be made available, by creating a prolonged release of protein therapeutic products into the market. By reducing dosing frequency and maintaining medicines at therapeutic levels for longer, it will also improve patient compliance.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4460
Published Date: Aug 25, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing digital drug delivery and increasing prevalence of chronic diseases are some of the major factors anticipated to drive the growth of the drug delivery system market.
The market is anticipated to attain a CAGR of ~11% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Gerreshelmer AG, Baxter, Nemara, Kindeva Drug Delivery, West Pharmaceutical Services Inc., Ypsomed, Medtronic Inc., E3D Elcam Drug Delivery Devices, Astra Zeneca, Merck KGaA, and others.
The diabetes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.